Clinical trial
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With…
NCT00090870 · Medical University of South Carolina, Other · Terminated
Key facts
| NCT number | NCT00090870 |
|---|---|
| Title | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma |
| Lead sponsor | Medical University of South Carolina, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2b, GM-CSF, thalidomide |
| Enrollment | 10 |
| Start date | Apr 1, 2002 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Sep 8, 2004 |
| Last update posted | Jul 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: